Bristol Myers’ Camzyos Achieves Phase 3 Success in Adolescent HCM Study
Bristol Myers Squibb announced its SCOUT-HCM Phase 3 trial met primary efficacy and safety endpoints for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, supporting a pediatric label expansion. The results bolster Camzyos’ growth trajectory following adult approvals and could drive incremental revenue from under-18 patients.
1. SCOUT-HCM Phase 3 Trial in Adolescents
Bristol Myers Squibb’s SCOUT-HCM study evaluated Camzyos (mavacamten) in patients aged 12–17 with symptomatic obstructive hypertrophic cardiomyopathy and met its primary efficacy and safety endpoints. These data pave the way for a pediatric label submission and expand Camzyos’ market beyond the adult oHCM population.
Related News
QCOM
Qualcomm Gains 3% on Samsung Strike Threat, Holds Talks on $5B Tenstorrent Deal
QCOM•
TJX
The TJX Companies Raises Full-Year EPS Guidance After Q1 EPS of $1.19 and 9% Revenue Growth
TJX•
SO
Georgia Natural Gas Greener Life Offsets 1 Billion Pounds of Carbon with 100,000 Customers
SO•
RIVN
Global EV Sales Reach 25% Share as Rivian Valuation Plummets 90%
RIVN•
DAR
Beyond Oil Targets $5M Run-Rate with 1Q26 US Rollouts in Fast-Food and Supermarkets
DAR•
Sources
F